There was no significant difference between IKZF3 amplification and IKZF3 wild type group considering sex (P = 0.14), age (P = 0.35), pTNM stage (P = 0.81), differentiation grading (P = 0.66), lymph node metastasis (P = 0.45), EBV infection (P = 0.62), tumor deposits (P = 0.89), vessel invasion (P = 0.74), nerve invasion (P = 0.41), and cancer related death (P = 0.12). This evidence concerns the gene IKZF3 and Epstein-Barr virus infection.